{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52"}]}],"title":"Stable MMR for 48 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46"}]}],"title":"Stable MMR for 96 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41"}]}],"title":"Stable MMR for 144 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38"}]}],"title":"Stable MMR for 192 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}],"title":"Stable MMR for 240 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}],"title":"Stable MMR for 288 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}],"title":"Stable MMR for 336 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}],"title":"Stable MMR for 384 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"Stable MMR for 432 weeks ["}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"description":"Percentage of participants who were in stable MMR (stable MMR=BCR-ABL ≤ 0.1% IS) at multiple timepoints after achievement of that response in the nilotinib re-initiation phase for those timepoints.","groups":[{"description":"If a patient had a confirmed loss of MR4 (two consecutive BCR-ABL1 \\>0.01% IS) or loss of MMR (BCR-ABL1 \\>0.1% IS) in the TFR phase, the patient restarted nilotinib treatment.","id":"OG000","title":"NTRI Phase"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Nilotinib treatment re-initiation (NTRI) Safety set included participants who achieved MMR at least once in nilotinib re-initiation phase","reportingStatus":"POSTED","timeFrame":"at 48 weeks, 96 weeks, 144 weeks, 192 weeks, 240 weeks, 288 weeks, 336 weeks, 384 weeks and 432 weeks after re-initiating Nilotinib in the NTRI Phase","title":"Percentage of Participants With Stable MMR in Nilotinib Re-initiation Phase","type":"SECONDARY","unitOfMeasure":"Participants"}